secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001558370-23-019019
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor completes HOPE-3 enrollment; Q3 net loss $6.4M, cash $28.5M
--------------------------------------------------------------------

- Completed targeted enrollment for HOPE-3 Phase 3 trial of CAP-1002 in Duchenne muscular dystrophy; interim futility analysis expected Q4 2023.
- FDA affirmed alignment on HOPE-3 design; BLA submission planned supported by Cohort A results.
- Q3 revenue $6.2M (from Nippon Shinyaku upfront recognition) vs $1.6M prior year; net loss $6.4M flat YoY.
- Cash $28.5M at Sept 30; subsequent $23M registered direct offering with Nippon Shinyaku extends runway into 2025.
- Appointed Michael Kelliher (Amgen/Horizon) to Board of Directors; advancing StealthX exosome platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/0001558370-23-019019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/capr-20231114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer